TRLV
Trulieve Cannabis Corp.
stock NYSE

i actually think it's better that this happened for TRLV (i also don't think this really means much anyway but to the extent it does). Basically TRLV whole business (at least bottom line) is medical. Future growth or at least what I can tell is Georgia and Texas medical. None of that affected by AU S3 delay. TRLV also hasn't really shown it is good at rec but is the best at medical from what we've seen. I actually think it would be bad for TRLV if Florida went rec. Why change what they are dominant at now?

And whether we like to admit it or not, there is definitely limited capital going into cannabis right now. I dont think the dams fully open to big institutions until theres full federal legalization or companies start showing massive growth again. So with that in mind there are only 2 big board listed companies today in the US - TRLV and GLAS. GLAS is absolute trash. So anyone looking for present day US exposure goes to TRLV.
(Side note: SNDL has some US exposure but it's smaller part of their portfolio. CGC i think is losing their US exposure. VFF has a greenhouse in TX but no license. CRON and OGI have big tobacco partners and could build but haven't today yet. So i just left those out and limited to TRLV and GLAS)
If adult use gets rescheduled, CURA, GTI, VRNO, etc all will uplist. And that is more capital competition for TRLV. So while the fundamentals don't get changed, the premium might.
Obviously i bought the dip haha.

i actually think it's better that this happened for TRLV (i also don't think this really means much anyway but to the extent it does). Basically TRLV whole business (at least bottom line) is medical. Future growth or at least what I can tell is Georgia and Texas medical. None of that affected by AU S3 delay. TRLV also hasn't really shown it is good at rec but is the best at medical from what we've seen. I actually think it would be bad for TRLV if Florida went rec. Why change what they are dominant at now?

And whether we like to admit it or not, there is definitely limited capital going into cannabis right now. I dont think the dams fully open to big institutions until theres full federal legalization or companies start showing massive growth again. So with that in mind there are only 2 big board listed companies today in the US - TRLV and GLAS. GLAS is absolute trash. So anyone looking for present day US exposure goes to TRLV.
(Side note: SNDL has some US exposure but it's smaller part of their portfolio. CGC i think is losing their US exposure. VFF has a greenhouse in TX but no license. CRON and OGI have big tobacco partners and could build but haven't today yet. So i just left those out and limited to TRLV and GLAS)
If adult use gets rescheduled, CURA, GTI, VRNO, etc all will uplist. And that is more capital competition for TRLV. So while the fundamentals don't get changed, the premium might.
Obviously i bought the dip haha.

Well… I was initially long this for the DEA judge final ruling which was expected in the next few days at most to confirm the schedule 3 recommendation. And with GLAS and TRLV being the only big board listed companies in the US it would be natural these would catch an algo explosion up….the pattern of news and rip in this sick sector is well known.
The judge announced a 2 week stay yesterday and blood bath ensued.
Then I chased the dip, a few times. And now I find myself more of an investoooorrr….
In hindsight it should have all went to Trlv for the recovery but…. You know

Solely TRLV, actually. Didn't realize everyone else closed so low. Damn. Rough day.

I just opened the largest SPY put position I've ever made in my life.
IDK why. Something feels wrong. All my stop triggers went off this past 2 weeks and I'm almost all cash, with the exception of Nintendo, Costco, and TRLV (which ate shit 16% today but I'm still green overall).

For example, this investment note on Trulieve that was written this morning cites lots of reasons for its pre-market decline...but the MM article about a stay was not one of them:
[Investing.com](http://Investing.com) \-- Shares of Trulieve Cannabis fell 6.5% in pre-open trading after the company’s announcement late Monday of an exclusive master licensing agreement with Connected Cannabis — covering the premium Alien Labs and Connected brands across Florida and Texas — prompted investors to reassess near-term cost and revenue implications rather than celebrate the strategic expansion. The deal, structured as a perpetual royalty-free license, broadens Trulieve’s product portfolio but introduces integration and marketing execution risk that markets appear to be pricing in this morning.
Adding to the pressure is a lingering insider selling overhang: CEO and Chairman Kim Rivers adopted a Rule 10b5-1 plan earlier this year to sell approximately 2.5 million shares, with a second tranche becoming eligible for sale after September 15, 2026. That window has been open for two weeks, and quarter-end portfolio rebalancing by institutional holders — who were drawn in partly by Trulieve’s addition to the S&P Total Market and [S&P Completion Indices](https://ca.investing.com/indices/s-p-completion) on September 22 — may be amplifying the selling activity.
The broader market backdrop provides little cushion. The S&P 500 is essentially unchanged today, while the Nasdaq is marginally in the red, offering no sector-wide tailwind for cannabis equities. Trulieve’s most recent quarterly results — revenue of $271 million in Q2 FY2026, down 10% year over year, alongside a large net loss driven by a non-cash deconsolidation charge — have left the fundamental picture mixed, making the stock sensitive to any shift in sentiment.
Taken together, the combination of market skepticism around the licensing deal’s near-term financial impact, the active CEO share-sale window, and a flat macro environment has converged to push [TRLV](https://ca.investing.com/equities/trulieve-cannabis) meaningfully lower in pre-market, even as the company’s longer-term positioning — including its NYSE listing, DEA registration milestones, and index inclusion — remains intact.
[](https://ca.investing.com/indices/s-p-completion)

Why is TRLV getting hit the hardest if medical S3 is not affected, which is primarily where they operate?

Smart move. I sold all my TRLV after hours yesterday. There is no hurry to buy anything now. I'm not selling my GTI and I will look to buy more at certain levels. I also sold my VFF. I can't give back profits anymore.

So terrified that I just bought a whack of TRLV mid-10s, and sold a few Jan puts.